Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.46 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.44 |
| ▸ | PNMT | P11086 | 1/20 | 0.44 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.44 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | CACNA1C | Q13936 | 5/20 | 0.41 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.41 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.41 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17614903 | 1.00 | MAPT (0.46) | MAPTADRA2APNMTADRA2BADRA2C | |
| SCHEMBL27693463 | 0.91 | MAPT (0.46) | MAPTADRA2APNMTADRA2BADRA2C | |
| SCHEMBL16135451 | 0.91 | MAPT (0.46) | MAPTADRA2APNMTADRA2BADRA2C | |
| SCHEMBL14402243 | 0.86 | ALDH1A1 (0.44) | MAPTADRA2APNMTADRA2BADRA2C | |
| SCHEMBL28788156 | 0.86 | MAPT (0.46) | MAPTADRA2APNMTADRA2BADRA2C | |
| SCHEMBL26597092 | 0.86 | MAPT (0.46) | MAPTADRA2APNMTADRA2BADRA2C | |
| SCHEMBL13547910 | 0.82 | ADRA2A (0.46) | MAPTADRA2APNMTADRA2BADRA2C | |
| SCHEMBL15630433 | 0.82 | PNMT (0.55) | MAPTADRA2APNMTADRA2BADRA2C | |
| SCHEMBL11030539 | 0.82 | PNMT (0.62) | ADRA2APNMTADRA2BADRA2C | |
| SCHEMBL11725913 | 0.82 | PNMT (0.62) | ADRA2APNMTADRA2BADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104640843-A | 1-(cycloalkyl-carbonyl)proline derivative | DAINIPPON SUMITOMO PHARMA CO | 2015-05-20 | — | — | CN | disclosed |
| CN-102174024-B | 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS INC | 2015-02-11 | — | — | CN | disclosed |
| US-8211935-B2 | Heterocyclic derivatives for modulation of calcium channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-07-03 | — | — | US | disclosed |
| CN-102174024-A | 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS INC | 2011-09-07 | — | — | CN | disclosed |
| US-20110178061-A1 | HETEROCYCLIC DERIVATIVES FOR MODULATION OF CALCIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-07-21 | — | — | US | disclosed |
| CN-1625400-B | 2, 4-pyrimidinediamine compounds and uses thereof | RIGEL PHARMACEUTICALS INC | 2011-04-13 | — | — | CN | disclosed |
| CN-101795711-A | chemical linkers and cleavable substrates and conjugates thereof | MEDAREX INC | 2010-08-04 | — | — | CN | disclosed |
| US-7569604-B2 | Heterocyclic derivatives for modulation of calcium channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-08-04 | — | — | US | disclosed |
| CN-101312748-A | Antibody-drug conjugates and methods of use | MEDAREX INC (US) | 2008-11-26 | — | — | CN | disclosed |
| CN-101171015-A | Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same | RENOVIS INC (US) | 2008-04-30 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178061-A1 | HETEROCYCLIC DERIVATIVES FOR MODULATION OF CALCIUM CHANNELS | CACNA1D, ORAI1, CACNA1C | MAPT 1243/4885ADRA2A 334/4885PNMT 2964/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.